As there is considerable clinical enthusiasm to understand which clinical STS will benefit from immune checkpoint blockade, the addition of intra-tumoral STING therapy may provide an opportunity to improve response rates across more STS subtypes. This evidence concerns the gene STING1 and telomere syndrome.